Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline
- Inflammatory bowel disease (IBD)
- IBD histology
- HSCT/BMT
- GVHD as a result of HSCT/BMT
- Comparing IBD and GVHD (1)
- Comparing IBD and GVHD (2)
- The intestinal epithelial barrier
- Intestinal epithelial permeability pathways
- Barrier dysfunction: increased MLCK expression
- The intestinal barrier in IBD (1)
- The intestinal barrier in IBD (2)
- The intestinal barrier and GVHD
- Intestinal barrier dysfunction & GVHD severity
- Is intestinal barrier loss required for GVHD?
- Irradiation is required for GVHD
- NK cells might be affected by irradiation
- Irradiation, intestinal barrier loss & NK cell depletion
- Intestinal barrier loss & NK cell depletion in GVHD
- Model for the intestinal barrier in GVHD
- Summary: the intestinal barrier in IBD and GVHD
- Targeted therapies in IBD and GVHD
- 3 targeted therapeutic approaches in IBD & GVHD
- Modulating cytokine/growth factor signaling
- Altering lymphocyte trafficking
- Restoring the epithelial barrier
- Summary (1)
- Summary (2)
- Thank you
Topics Covered
- Comparing/contrasting inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD)
- Molecular aspects of intestinal epithelial barrier loss in IBD & GVHD
- Emerging therapeutic strategies targeting the intestinal barrier in IBD & GVHD
Links
Categories:
Therapeutic Areas:
Talk Citation
Nalle, S. (2015, December 31). Therapeutic targeting of the intestinal barrier in inflammatory bowel disease and graft-versus-host disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/DZEN4883.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Sam Nalle has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Sam Nalle,
I'm a postdoctoral fellow
at Genentech,
and I'll be discussing
therapeutic targeting
of the intestinal barrier
in inflammatory bowel disease
and graft-versus-host disease.
0:14
In this lecture I will compare
and contrast inflammatory
bowel disease,
IBD, and graft-versus-host
disease, GVHD.
I'll take a detailed look
at the intestinal barrier
in IBD and GVHD
and I will discuss
therapeutic targeting
of the intestinal barrier
in IBD and GVHD.
The goal of this lecture
is to understand
the biological basis for
rational therapeutic targeting
of the intestinal barrier
in IBD and GVHD.
0:41
Starting with inflammatory
bowel disease,
IBD is comprised
of Crohn's disease
and ulcerative colitis.
Ulcerative colitis
involves only the colon
whereas Crohn's disease
can affect
the entire
gastrointestinal tract.
Symptoms include
malabsorption, nausea,
bloody or mucoid diarrhea,
and weight loss.
Etiology involves
a combination of genetic
and environmental factors,
and IBD is more prevalent
in developed countries
in North America and Europe.
1:08
I'll give the histology
of Crohn's disease
for some more detailed
description of IBD.
Inactive IBD is characterized
by crypt
architectural distortion,
fibrosis,
or epithelial metaplasia,
but no active
inflammatory infiltrates
such as neutrophils
or eosinophils.
Mild activity is characterized
by rare intraepithelial
neutrophils or eosinophils,
and increased numbers
of neutrophils or eosinophils
within the lamina propria.
Moderate activity contains
frequent intraepithelial
neutrophils or eosinophils,
lamina propria distortion,
and markedly increased
numbers of neutrophils
or eosinophils
within the lamina propria.
Finally, severe activity
is characterized
by numerous crypt abscesses,
erosions or ulcerations
and focal sheets
of neutrophils or eosinophils
within the lamina propria.
Hide